Skip to main content

Market Overview

Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications

Share:
Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications
  • Mirimus Inc has collaborated with Biogen Inc (NASDAQ: BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. 
  • Terms of the collaboration are not disclosed.
  • Under the agreement, Mirimus will engineer RNAi-based therapeutics that Biogen will assess to determine feasibility in potential neurological disease settings. 
  • If feasibility is established, the companies will have the option to pursue pre-clinical development of the asset(s).
  • Price Action: BIIB shares are down 0.75% at $320.06 during the market session on the last check Wednesday.
 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com